Compares two PET imaging agents for finding prostate cancer in the same patients
Compares two PET scan tracers in adults newly diagnosed with prostate cancer.
Plain-language title generated from the registry record
Registry title: 68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with confirmed prostate cancer who have not been treated yet. Each man gets two PET/CT scans, with 68Ga-PSMA-11 and 68Ga-P16-093, within a week.
- Age
- 18 to 90 years
- Sex
- Men only
- Disease stage
- Primary prostate cancer, confirmed by tissue examination (histology)
- Earlier treatment
- No prior treatment for the prostate cancer
Main reasons for not taking part
- Known allergy against PSMA
- Any medical condition that, in the investigator's opinion, may significantly interfere with following the study
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT05324332, who can take part
Where in China
- Peking Union Medical College HospitalBeijing, ChinaContact: Zhaohui Zhu, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT05324332
- Record updated
- 22 September 2025
- Original description
Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the most widely studied 68Ga-PSMA-11. This pilot study was evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients.Read full original descriptionShow less
A Pilot Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 in the Same Group of Primary Prostate Cancer Patients
Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the most widely studied 68Ga-PSMA-11. This pilot study was evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients.
Inclusion: histologically confirmed untreated primary prostate cancer patients; 68Ga-PSMA-11 and 68Ga-P16-093 PET/CT within a week; signed written consent.
Exclusion: known allergy against PSMA; any medical condition that in the opinion of the investigator may significantly interfere with study compliance.